OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company
Rhea-AI Summary
OneMedNet (Nasdaq: ONMD) announced a new agreement to supply de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. Using its iRWD™ Platform, OneMedNet reports project feasibility was completed within minutes, data validation within a week, and a contract signed within three weeks of initial contact.
The customer is using OneMedNet’s first-party, regulatory decision-grade data to develop and validate AI models aimed at accelerating drug discovery and development. OneMedNet’s iRWD network now includes more than 90 million patient journeys, 270 million studies, and over 2,300 healthcare partner sites, spanning multimodal data such as radiology, cardiology, EEG, ECG, and de-identified electronic health records, with optional tokenized linkage for longitudinal analysis, according to OneMedNet.
Positive
- None.
Negative
- None.
Market reaction after AI data partnership: ONMD +6.38%
Following this news, ONMD has gained 6.38%, reflecting a notable positive market reaction. Argus tracked a trough of -8.2% from its starting point during tracking. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.62. Trading volume is exceptionally heavy at 7.8x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 28 | AI data agreement | Positive | +17.0% | Agreement to supply regulatory-grade RWD for foundational AI model development |
| Apr 06 | AI financial results | Positive | +2.4% | Reported 2025 financial results while advancing AI-driven iRWD platform capabilities |
| Apr 01 | AI collaboration | Positive | -0.8% | Collaboration provided oncology real-world data access for drug-development model work |
| Jan 22 | FDA clearance support | Positive | +12.1% | RWD supported FDA 510(k) clearance for AI intracranial hemorrhage software |
| Nov 10 | AI subscription launch | Positive | +4.7% | Introduced Palantir-powered iRWD subscriptions for live feeds and conversational search |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged announcements produced four positive and one negative 24-hour price reactions, indicating generally positive but inconsistent alignment.
Key Terms
real-world data medical
de-identified medical
electronic health records medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Customer selects OneMedNet for the full-fidelity studies and regulatory decision-grade quality required to develop AI models that accelerate drug development
MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. OneMedNet's iRWD™ Platform enabled cohort feasibility within minutes, data validation within a week, and signed contract within three weeks of initial contact, and is now delivering the data to support the customer's development and validation of AI models designed to accelerate and improve how new therapies are discovered and developed.
The customer selected OneMedNet after recognizing that building AI models capable of genuine innovation in drug development requires full-fidelity clinical studies at a level of quality that only data directly sourced from healthcare providers can deliver. OneMedNet’s network provides that fidelity at scale, with the curation, de-identification, and clinical integrity standards required for AI model training and validation.
“Healthcare innovators are coming to OneMedNet because they see what it takes to build AI that performs in the real world: private clinical data sourced directly from healthcare providers,” said Aaron Green, President & CEO of OneMedNet. “OneMednet provided first-party data is what enables our customers to accelerate the development and validation of their AI models, and we believe the surge in demand we are experiencing reflects it. Our iRWD platform enables this pace — feasibility, validation, contracting, and delivery in a matter of weeks — and the ease of doing business customers can expect.”
The agreement underscores the growing role of OneMedNet’s iRWD™ network — now exceeding 90 million patient journeys, 270 million studies, and more than 2,300 healthcare partner sites — as foundational infrastructure for AI model development across the healthcare and life sciences ecosystem. OneMedNet’s multimodal data spans Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records, with optional tokenized linkage for longitudinally connected, multimodal datasets.
Agreement highlights:
- Project feasibility completed within minutes.
- First-party, direct-from-source data delivered from a live network of Healthcare Provider partner sites.
- Regulatory decision-grade quality spanning de-identified medical imaging and comprehensive clinical records, suitable for AI model development and downstream regulatory use.
- Continued commercial momentum reflecting surging demand for private healthcare clinical data sourced directly from healthcare providers.
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform is powered by Palantir Foundry and supports applications ranging from drug development and regulatory submissions to foundational AI model training. Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the ability and benefits of our iRWD platform and the demand for our products, our ability to achieve our operational strategies, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
SOURCE: ONEMEDNET CORPORATION
